PL2744826T3 - Combination therapy with an anti-cd19 antibody and a purine analog - Google Patents

Combination therapy with an anti-cd19 antibody and a purine analog

Info

Publication number
PL2744826T3
PL2744826T3 PL12745883T PL12745883T PL2744826T3 PL 2744826 T3 PL2744826 T3 PL 2744826T3 PL 12745883 T PL12745883 T PL 12745883T PL 12745883 T PL12745883 T PL 12745883T PL 2744826 T3 PL2744826 T3 PL 2744826T3
Authority
PL
Poland
Prior art keywords
antibody
combination therapy
purine analog
purine
analog
Prior art date
Application number
PL12745883T
Other languages
Polish (pl)
Inventor
Jutta AMERSDORFFER
Stefan Steidl
Mark Winderlich
Susanne KROHN
Lisa Rojkjaer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PL2744826T3 publication Critical patent/PL2744826T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL12745883T 2011-08-16 2012-08-14 Combination therapy with an anti-cd19 antibody and a purine analog PL2744826T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660 2011-08-16
PCT/EP2012/065904 WO2013024095A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a purine analog
EP12745883.4A EP2744826B1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti-cd19 antibody and a purine analog

Publications (1)

Publication Number Publication Date
PL2744826T3 true PL2744826T3 (en) 2022-05-30

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12745883T PL2744826T3 (en) 2011-08-16 2012-08-14 Combination therapy with an anti-cd19 antibody and a purine analog

Country Status (25)

Country Link
US (3) US20140227277A1 (en)
EP (2) EP4083071A3 (en)
JP (1) JP6114273B2 (en)
KR (3) KR102117202B1 (en)
CN (1) CN103703027B (en)
AU (1) AU2012296905B2 (en)
BR (1) BR112013033916B1 (en)
CA (1) CA2841738C (en)
CY (1) CY1125148T1 (en)
DK (1) DK2744826T3 (en)
ES (1) ES2909720T3 (en)
HR (1) HRP20220224T1 (en)
HU (1) HUE058855T2 (en)
IL (1) IL230295B (en)
LT (1) LT2744826T (en)
MX (1) MX353589B (en)
PL (1) PL2744826T3 (en)
PT (1) PT2744826T (en)
RS (1) RS63121B1 (en)
RU (1) RU2664462C9 (en)
SG (1) SG10201606788VA (en)
SI (1) SI2744826T1 (en)
SM (1) SMT202200160T1 (en)
WO (1) WO2013024095A1 (en)
ZA (1) ZA201401835B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (en) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Use of deguelin as a supplementary therapy for chronic lymphoid leukemia
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment for chronic lymphocytic leukemia (cll)
EP3157553A4 (en) * 2014-06-16 2018-02-28 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
EP3603672B1 (en) * 2015-05-26 2026-04-22 Incyte Corporation Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
MX392561B (en) * 2015-08-21 2025-03-24 Morphosys Ag SYNERGISTIC COMBINATION OF AN ANTI-CD19 ANTIBODY AND A PHOSPHOINOSITIDE 3-KINASE INHIBITOR FOR USE IN THE TREATMENT OF NON-HODGKIN'S LYMPHOMA, CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR ACUTE LYMPHOBLASTIC LEUKEMIA.
CN115932265B (en) * 2016-05-30 2026-04-14 因塞特公司 Methods of predicting therapeutic benefit of CD19 antibody treatment in a patient
KR20230028571A (en) 2016-10-28 2023-02-28 모르포시스 아게 Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
IL297461B2 (en) * 2017-05-31 2024-09-01 Morphosys Ag A therapeutic paradigm for combined anti-CD19 antibody therapy and Ventoclax
EP3652206A1 (en) 2017-07-10 2020-05-20 International-Drug-Development-Biotech Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics
KR20200030337A (en) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
CN119013293A (en) * 2021-12-22 2024-11-22 因赛特公司 Therapeutic paradigm of anti-CD 19 antibody therapy
IL325762A (en) 2023-07-13 2026-03-01 Christian Albrechts Universit?T Zu Kiel Humanized anti-cd7 antibody

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11852A (en) 1854-10-31 Abraham bassford
US106A (en) 1915-08-24 Specipication
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
PL195870B1 (en) * 1998-08-11 2007-11-30 Biogen Idec Inc Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
DE60226641D1 (en) 2001-12-03 2008-06-26 Amgen Fremont Inc ANTIBODY CATEGORIZATION BASED ON BINDING CHARACTERISTICS
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
EP2270050B1 (en) * 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (en) * 2006-08-14 2013-06-28 Xencor Inc Optimized antibodies that target CD19
JP5401314B2 (en) 2006-09-08 2014-01-29 メディミューン，エルエルシー Humanized anti-CD19 antibodies and their use in the treatment of cancer, transplantation and autoimmune diseases
AU2008260498B2 (en) * 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
JP2012518404A (en) 2009-02-23 2012-08-16 グレンマーク・ファーマシューティカルズ・エスエー Humanized antibodies that bind to CD19 and uses thereof
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
RU2012109451A (en) * 2009-08-14 2013-09-27 Роше Гликарт Аг COMBINED THERAPY BASED ON AFUCHOSILY ANTIBODY TO CD20 IN COMBINATION WITH FLUDARABIN AND / OR MITOXANTRON
TWI409079B (en) * 2009-08-14 2013-09-21 Roche Glycart Ag Combination therapy of atypical fucosylated CD20 antibody and bendamustine
EP2501237A1 (en) * 2009-11-06 2012-09-26 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Also Published As

Publication number Publication date
AU2012296905B2 (en) 2017-01-05
ES2909720T3 (en) 2022-05-10
RU2664462C2 (en) 2018-08-17
EP2744826A1 (en) 2014-06-25
MX2013014935A (en) 2014-07-09
SG10201606788VA (en) 2016-09-29
US20200352975A1 (en) 2020-11-12
JP2014525925A (en) 2014-10-02
US20140227277A1 (en) 2014-08-14
HRP20220224T1 (en) 2022-04-29
EP4083071A2 (en) 2022-11-02
KR102117202B1 (en) 2020-06-01
KR20200060779A (en) 2020-06-01
JP6114273B2 (en) 2017-04-12
ZA201401835B (en) 2015-06-24
US20240424012A1 (en) 2024-12-26
PT2744826T (en) 2022-05-19
SI2744826T1 (en) 2022-05-31
RU2014103490A (en) 2015-09-27
CN103703027A (en) 2014-04-02
EP4083071A3 (en) 2023-02-22
KR20140071368A (en) 2014-06-11
HUE058855T2 (en) 2022-09-28
EP2744826B1 (en) 2022-02-09
CA2841738C (en) 2022-12-06
RU2664462C9 (en) 2018-09-28
NZ617771A (en) 2016-01-29
SMT202200160T1 (en) 2022-05-12
CA2841738A1 (en) 2013-02-21
DK2744826T3 (en) 2022-03-28
RS63121B1 (en) 2022-05-31
WO2013024095A1 (en) 2013-02-21
MX353589B (en) 2018-01-19
KR20190094478A (en) 2019-08-13
CN103703027B (en) 2018-01-12
IL230295B (en) 2018-03-29
BR112013033916B1 (en) 2022-11-16
LT2744826T (en) 2022-04-25
BR112013033916A2 (en) 2017-11-28
CY1125148T1 (en) 2024-12-13

Similar Documents

Publication Publication Date Title
ZA201401835B (en) Combination therapy with an anti-cd19 antibody and a purine analog
IL281250A (en) Anti-phf-tau antibodies and their uses
DK2729170T3 (en) Antibody variants and uses thereof
IL232407B (en) Assays and methods for selecting a treatment regimen for a subject with depression
EP2756094A4 (en) Anti-b7-h4 antibodies and their uses
EP2712427A4 (en) Two component source seismic acquisition and source de-ghosting
GB201110783D0 (en) Methods and uses
IL230293B (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
GB201116774D0 (en) Uses and methods
IL224953A (en) Theobromine in combination with an expectorant or a mucolytic for use in therapy
EP2716359A4 (en) Complex and uses thereof
EP2721788A4 (en) Methods and arrangement for dispatching requests
GB201108490D0 (en) Methods and uses
AU340918S (en) A vehicle and a toy vehicle
ZA201401628B (en) Antiballistic article with resin
GB201114341D0 (en) Reagent and use
GB201119443D0 (en) GoWinging Concept and patent
IL215565A0 (en) Bed with accessible and usable space
GB201107656D0 (en) Short back and sides
GB201102221D0 (en) Inventions and therapy